Search results
Showing 1861 to 1875 of 2579 results for methods
Azacitidine for treating relapsed or refractory angioimmunoblastic T-cell lymphoma [ID3864]
Discontinued Reference number: GID-TA10750
Discontinued Reference number: GID-TAG377
Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]
In development Reference number: GID-TA11272 Expected publication date: TBC
Discontinued Reference number: GID-TA10144
Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [ID12203]
In development Reference number: GID-TA11781 Expected publication date: TBC
Gefurulimab for treating antibody-positive generalised myasthenia gravis [TSID12256]
In development Reference number: GID-TA11848 Expected publication date: TBC
In development Reference number: GID-TA11372 Expected publication date: TBC
In development Reference number: GID-TA11709 Expected publication date: TBC
In development Reference number: GID-TA11457 Expected publication date: TBC
Gantenerumab for treating early Alzheimer's disease [ID6142]
In development Reference number: GID-TA11269 Expected publication date: TBC
In development Reference number: GID-TA11491 Expected publication date: TBC
Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]
Discontinued Reference number: GID-HST10004
GID-MT563 NPi-200 for pupillary light reflex in critical care patients
Discontinued Reference number: GID-MT563
Cabozantinib with atezolizumab for untreated advanced hepatocellular carcinoma [ID3940]
Discontinued Reference number: GID-TA10830
Venetoclax with ibrutinib and obinutuzumab for untreated chronic lymphocytic leukaemia ID1270
Discontinued Reference number: GID-TA10211